|
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Conference/Miscellaneous
BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry players to dive into a vigorous discussion on the central topics of the rapidly developing radiotheranostics market. The Forum will discuss solutions to challenges in supply chain, upscaling and patient access as well as the latest theranostic concepts. “We are excited to host the first edition of the Radionuclide Theranostics Forum in Boston and to bring together leading experts in the field of radiotheranostics. The event will build on the momentum of recent developments and approvals and foster discourse on current and future challenges," said Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “More than three decades of experience in handling and manufacturing radiopharmaceuticals and radioactive medical devices, developing technical solutions and processes, enable us to fully assess and support concepts and thus facilitate partner projects. We are confident that many of the ideas generated together during our Forum will be an important foundation for the development of precision oncology in North America and globally in the years to come." The Boston Radionuclide Theranostics Forum is initiated and sponsored by Eckert & Ziegler and organized together with the support of the German-American Business Council of Boston (GABC). The half-day event will be hosted at the Boston offices of the international law firm Morrison & Foerster LLP. More than a dozen international experts and executives from clinic, industry, research and beyond are scheduled to speak in panel discussions and fireside chats. Attendance is by invitation only and is at capacity. About Eckert & Ziegler. Contact
30.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | karolin.riehle@ezag.de |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1643195 |
| End of News | EQS News Service |
|
|
1643195 30.05.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
